Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
By C. Teunissen, I. Verberk, Elisabeth H. Thijssen, L. Vermunt, Oskar Hansson, Henrik Zetterberg, W. M. van der Flier, Michelle M. Mielke, M. del Campo. Lancet Neurology, 2021
800 citations recorded by the source corpus.
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.
Subfields: Molecular Biology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/f8f367cb900928ad0065b297064037bf4b5d4ed5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Physiology
In Psychiatry and Mental health
Citations in the corpus
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup (2024, positive): “31,32,175 PET imaging of synapses has also entered the research arena based on ligands that bind to the synaptic vesicle glycoprotein 2A, a presynaptic component that may be lost with neurodegeneration.”